TRASTUZUMAB DERUXTECAN FOR DUMMIES

Truqap is often a kinase inhibitor that works by blocking pathways that assist the most cancers cells survive and develop, so reduces most cancers development. Truqap is from a category of medicines identified as an AKT inhibitor. Truqap acquired FDA approval on November 17, 2023, just after beneficial effects through the CAPItello-291 Section III